Anti-VEGF Agents – The Importance of Early Switching when Treatment Fails

anti-VEGF 300X165px-01

In patients with diabetic macular oedema, aflibercept is the only globally approved anti-VEGF agent that binds all ligands of VEGF receptor 1.

You will learn:
Factors affecting the choice of anti-vascular endothelial growth factor (VEGF) agent for treating diabetic macular oedema (DME)
Clinical trial and real-world evidence for maximising vision gains while reducing the treatment burden for patients with DME
The principles of anti-VEGF treatment regimens for neovascular age-related macular degeneration (nAMD)
The relevance of the molecular properties of anti-VEGF agents with regard to switching therapy.


ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don’t upload these yourself.

To access this module, please register or login: